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CASE PRESENTATION
A 23-year-old man was referred to Peking University
First Hospital with a 4-month history of intermittent
hemoptysis. One month before admission, he experienced
severe hemoptysis with cough and respiratory distress. His
hemoglobin was 71.0 g/l, urinalysis revealed protein 1þ ,
and red blood cells 3–5/high-power field (HPF). Arterial
blood gas analysis showed pH 7.385, PO2 58 mm Hg, PCO2
40 mm Hg, and SaO2 88%. Chest radiograph showed
diffusely parenchymal shadows in both lungs. He was
diagnosed as having a pulmonary infection with
respiratory failure type I and was treated with ceftazidime
and erythromycin, but no improvement was obtained
after 3 weeks. One week before admission, an anti-
glomerular basement membrane (GBM) antibody was
detected positive by enzyme-linked immunosorbent assay
(ELISA) using purified bovine a(IV)NC1 as solid-phase
antigen. He was then referred to our hospital.
The patient was a car repairman with a 5-year exposure
to gasoline and diesel. He smoked 1–2 packs of cigarettes
per day for 4 years.
Physical examination revealed a well-nourished man
with no edema or rash. The temperature was 36.81C,
blood pressure 130/85 mm Hg, and pulse 90/min. The
heart rate and rhythm was regular. Moist rales could
be heard in both lungs. The abdomen was soft and
non-tender without organomegaly.
Laboratory data on admission were as follows: white
blood cells 12.8 109/l (normal range, 3.5–9.5 109/l),
hemoglobin 62.0 g/l (137–179 g/l), platelet 178 109/l
(100–300 109/l). Hepatic function was normal.
Serum creatinine was 94.0mmol/l (44–133mmol/l)
and blood urea nitrogen was 6.3 mmol/l (1.8–7.1 mmol/l).
Electrolytes were in the normal range. Serum albumin was
39.6 g/l (35–50 g/l). Urinalysis revealed red blood
cells 3–5/HPF (0–3/HPF) and dysmorphic red cells and the
24-h urine protein was 0.87 g (o0.15 g/24 h). Erythrocyte
sedimentation rate was 14 mm/1 h (o15 mm/1 h).
C-reactive protein, rheumatoid factor, antineutrophil
cytoplasmic antibodies, and antinuclear antibodies
were all negative. Anti-GBM antibodies were positive
at 23% tested by ELISA as described above (normal
range, o13%), with a titer of 1:400.
Although there was a broad differential, including
small vessel vasculitis, systemic lupus erythematosus,
pulmonary infection, tuberculosis, and heart failure, the
clinical presentation and the laboratory workup were
most compatible with a diagnosis of anti-GBM disease
with Goodpasture’s syndrome. After admission, a renal
biopsy was performed.
RENAL BIOPSY FINDINGS
On light microscopy, the patient had 12 glomeruli with
no crescent formation. The glomeruli showed mild proli-
feration of mesangial cells (Figure 1). Immunofluorescence
showed linear staining of IgGþ þ and C3þ þ along
GBM (Figure 2). Serum anti-GBM antibodies were further
confirmed by Western blot analysis using purified human
a(IV)NC1 as antigen (Figure 3). The antigen specificity was
identified by ELISA using recombinant human a3(IV)NC1
as solid-phase antigen. The IgG subclasses of the antibodies
were restricted to IgG4.
CLINICAL FOLLOW-UP
The patient was treated with prednisone 1 mg/kg/day for 8
weeks, with gradual tapering off within 6 months. Carbon
monoxide transfer factor, arterial blood gas analysis, chest
radiography, serum creatinine, and urinalysis were per-
formed every 2 days. Under such a rigorous monitoring for
lung hemorrhage and renal function, no plasmapheresis
or cyclophosphamide was given to the patient. After 2 weeks,
his hemoptysis stopped, and hematuria and proteinuria
disappeared simultaneously. Six weeks after commencing the
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treatment, his serum anti-GBM antibodies became negative.
After discharge, the patient has been followed up for 7 years.
His serum creatinine is 80–100 mmol/l and urine examination
is normal. No relapse of hemorrhage, hematuria, or
proteinuria has been observed.
DISCUSSION
Anti-GBM disease is characterized by the formation and
deposition of antibodies on the basement membranes of
glomeruli and alveoli.1 Most patients present with both
alveolar hemorrhage and renal involvement. Collectively, this
syndrome is known as the classic form Goodpasture’s
syndrome, and is frequently accompanied by extensive and
rapidly progressive glomerulonephritis. The introduction of
combined therapy with immunosuppressive agents and
plasmapheresis has improved the prognosis of this disease.2
However, Goodpasture’s syndrome continues to be associated
with a high mortality of 11%, and high morbidity, where
40% of patients might expect to become dialysis-depen-
dent.1,3 Over the past several years, a subgroup of patients
with only minimal evidence of renal dysfunction had been
described largely because of improved immunodiagnostic
procedures. These patients provide valuable insights into
the pathogenesis of anti-GBM disease.
The clinical and pathological characteristics of anti-GBM
disease with normal renal function
This subgroup of patients with anti-GBM disease and normal
renal function usually present mainly with lung hemorrhage,
which ranges from some blood streaks in the sputum to
extensive hemoptysis and respiratory failure requiring
intubation and mechanical ventilation. The urinary sediment
examination had been reported as normal in occasional
patients,4–6 but for the most part demonstrated the presence
of hematuria and proteinuria.7–12 Macroscopic hematuria
and hypertension are rare in these patients.11 However, a
moderate to severe anemia could be a symptomatic cue to the
consideration of this disease.4–6,8,10,11 Systemic symptoms
(malaise, fever, or weight loss) are less common in these
patients compared with those with renal impairment. These
symptoms might be from the consequence of inflammation
associated with glomerulonephritis, or be the symptoms of
renal failure. Renal pathological examination generally
reveals a mild mesangial proliferative glomerulonephritis.
In some cases, a few cellular crescents may also be observed,
but usually less than 50% of total glomeruli.9 In general,
Figure 1 | Light microscopic examination revealed mild
mesangial proliferative glomerular nephritis ( 200).
Figure 2 | Immunofluorescence revealed linear staining of IgG
along GBM ( 400).
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Figure 3 | Western blot analysis using purified human a(IV)NC1
as antigen. Lane (1) blank control; lane (2) sera from a healthy
blood donor as negative control; lane (3) sera from a known
patient with Goodpasture’s syndrome with severe renal damage
as positive control; lane (4) sera from the current patient.
1404 Kidney International (2007) 72, 1403–1408
t h e r e n a l c o n s u l t Z Cui et al.: Anti-GBM with normal renal function
these patients have an excellent prognosis compared with the
classic Goodpasture’s syndrome. Indeed, renal function is
preserved in the majority of patients, although a slow
progression to renal failure had been observed in some. The
clinical presentation of patients with anti-GBM disease and
normal renal function is variable (similar to individuals with
renal impairment). Data from the published articles are
summarized in Table 1.4–12
The case presented here demonstrates some typical
features of Goodpasture’s syndrome. They are usually young,
male and cigarette smokers, presenting with pulmonary
hemorrhage and glomerulonephritis with or without renal
dysfunction. Our patient also had a history of exposure to
hydrocarbon fumes. However, the minor hematuria and
proteinuria were overlooked when he presented to a local
hospital. Thus, the renal involvement was not incorporated
into the formulation of the differential diagnosis for causes
of the intra-alveolar hemorrhage. He was suspected to have
pulmonary infection, pulmonary tuberculosis, tumor, or
idiopathic pulmonary hemosiderosis. He was treated with
antibiotics for 3 weeks for suspected infection, without any
improvement, before the detection of anti-GBM antibodies
in his sera. This patient’s history highlights the importance
for physicians to consider the diagnosis of anti-GBM disease
in patients with pulmonary hemorrhage, even when, as in
this patient, the renal function was normal and the urinalysis
revealed minimal abnormalities or no abnormalities (Table 2).
The evidence of anti-GBM antibodies detected in sera or
renal tissue is of vital importance in the diagnosis of anti-
GBM disease with normal renal function. The circulating
antibodies in the current case were demonstrated cautiously
by ELISA using purified bovine a(IV)NC1 and recombinant
human a3(IV)NC1 as solid-phase antigen, respectively,
and were further confirmed by Western blot analysis
using purified human a(IV)NC1 as antigen (Figure 3). The
deposition of antibodies in renal tissue was demonstrated by
linear staining of IgGþ þ and C3þ þ along GBM in
immunofluorescence assay of renal biopsy (Figure 2). Thus,
considering the clinical features of pulmonary hemorrhage
and mild proteinuria and hematuria, the diagnosis of anti-
GBM disease was confirmed.
The prevalence of anti-GBM disease with normal kidney
function
Patients with anti-GBM disease with normal kidney function
are not uncommon. In Peking University First Hospital, the
prevalence is approximately 3%.12 Other studies had found
that 15–36%4–12 of patients with anti-GBM disease have
normal kidney function. This variation might be due in part
to ‘normal’ kidney function being defined by levels of serum
creatinine, creatinine clearance, or clear urinary sediment.
An alternative explanation may be that anti-GBM disease
is recognized early, since there is heightened awareness of
anti-GBM disease as one potential cause of hemoptysis.13,14
We have also speculated that this subgroup of patients
with anti-GBM disease with normal kidney function is
recognized frequently because of improved immunodiagnos-
tic techniques. Diagnosis of anti-GBM disease is based on the
detection of anti-GBM antibodies in serum or in tissue, and a
positive serum assay is diagnostic of the disease. The ELISA
and radioimmunoassay are the most sensitive and specific
methods. Indeed, false-negative results had been reported
with serum indirect immunofluorescence assays using frozen
human kidney sections as substrate. Therefore, a negative
result with indirect immunofluorescence assay does not
exclude anti-GBM disease. Furthermore, ELISA and radio-
immunoassay are more convenient and amenable to be used
as screening tests in the detection of anti-GBM antibodies.
The likelihood of pulmonary involvement is probably
increased among those who smoke15 or have been exposed to
organic solvents.16 The permeability of lung capillaries is
increased and thereby enables circulating antibody to reach
the alveolar basement membrane. Furthermore, smoking
and inhalation of hydrocarbon fume themselves may damage
the alveolar basement membrane and thereby induce the
formation of antibasement membrane antibodies, and by
crossreacting with GBM, cause nephritis and hemorrhage.
Linear immunoglobulin deposition along alveolar basement
membranes is diagnostic of antibasement membrane disease,
especially when lung hemorrhage is the main manifestation.
However, a significant incidence of false-negative results of
immunofluorescent microscopy has been found with trans-
bronchial biopsy specimens, thus is not a reliable method
to exclude anti-GBM disease.5 This shortcoming leads us
to ELISA or radioimmunoassay for anti-GBM antibodies
in serum as a method of anti-GBM disease detection. This
approach has been suggested in the investigation of alveolar
hemorrhage syndromes with or without renal damage,
and has been recommended before diagnosing idiopathic
pulmonary hemosiderosis.
The relationship between anti-GBM antibodies and renal
function
Earlier data indicate that patients with anti-GBM disease with
normal kidney function usually have a lower level of
circulating anti-GBM antibodies than those with significant
renal impairment.8,11,17 The titer of anti-GBM antibodies of
this patient was 1:400, whereas of patients with classic
Goodpasture’s syndrome it was approximately 1:1000.18 To
date, the observation of lower levels of circulating anti-GBM
antibodies remained the most significant difference between
patients with normal and impaired kidney function.8,11,17
This case also supports the contention that lower levels of
circulating anti-GBM antibodies might correlate with better
preserved renal function. The correlation between antibody
titers and the serum creatinine on diagnosis or the prognosis
of renal function has been reported by us and other
investigators previously.12,19,20
Another mechanism by which anti-GBM antibodies may
vary between patients is the physiochemical characteristics of
the immunoglobulin present. The subclasses of IgG anti-
bodies might be different between patients. Previous studies
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have implicated subclasses IgG1 and IgG4 in the majority
of cases of Goodpasture’s syndrome.21,22 IgG subclasses of
serum anti-GBM antibodies in the current patient, tested by
ELISA, revealed a restriction of IgG4 activity. It has been
suggested that IgG4 subclass dominance could be explained
by chronic antigen stimulation. In the patient reported
herein, a possible explanation was the chronic exposure to
gasoline and smoking, which might lead to the exposure of
the Goodpasture antigen. Additionally, different IgG sub-
classes have different biological properties; for example, IgG4,
unlike IgG1, does not efficiently bind C1q and therefore does
not activate the classical pathway of complement. As well, the
IgG Fc receptors on mononuclear macrophage poorly bind
IgG4. Thus, IgG4 is unlikely to trigger severe inflammatory
damage in the glomeruli. We have observed previously that
anti-GBM antibodies in patients with mild renal dysfunction
(serum creatinineo300 mmol/l) were predominantly of IgG4
subclasses (75%),23 which supports the speculation that IgG
subclasses of anti-GBM antibodies may be associated with
different clinical presentations and disease progression.
Table 1 | Findings of patients with anti-GBM disease and normal renal function
No. 1 2 3 4 5 6 7
Year reported 1975 1981 1981 1990 1993 1993 1996
Journal Ann Intern Med4 Clin Nephrol8 Clin Nephrol8 Am Rev Resp
Dis5
Am J Nephrol9 Nephrol Dial
Transplant6
Nephrol Dial
Transplant10
Age/gender 18/M 18/M 20/M 20/M 23/F 24/M 22/M
Exposure to
gasoline fumes
N Y Y N N Y Y
Smoke N Y Y Y Y N Y
Clinical features
Lung Hemoptysis Hemoptysis Hemoptysis Hemoptysis Upper
respiratory tract
infection
N Hemoptysis
Chest
radiograph
Diffuse mottled
opacity over
both lung fields
Intra-alveolar
shadowing in
both lungs
Widespread
fine nodular
shadowing in
both lungs
Right upper
lobe infiltration
None Bilateral
alveolar
densities
Bilateral mid-
and lower-zone
consideration
Urinalysis Normal Upr 1 g/24 h,
30–100 106
red cells/l
Upr 0.24 g/24 h,
less than
1 106 red
cells/l
Normal Upr 2.88 g/24 h,
red cells 20–40/
HPF
Normal Microscopic
hematuria and
proteinuria
Hemoglobin 40 g/l 43 g/l 130 g/l 80 g/l 146 g/l 76 g/l 75 g/l
Circulating
anti-GBM
antibodies
None (+) (+) () () () (+)
Other
antibodies
ANA (), RF(),
Coombs’
test()
Coombs’ test
()
None ANA (), RF() ANA (), ANCA
()
ANA () ANA (), ANCA
()
Biopsy
IF Linear IgG
deposition
along GCW
Linear IgG 3+
and C3 1+
deposition
along GCW
Linear IgG
deposition
along GCW
Linear IgG 4+
deposition
along GCW
Linear IgG 3+
deposition
along GCW
Linear IgG and
C3 deposition
along GCW
Linear
deposition of
IgG in alveoli
LM Mild increase in
mesangial
prominence
Glomerular
swollen and
hypercellular, 2/
20 glomeruli
showed
epithelial
crescents
Mild segmental
increase in
mesangial
matrix and
cellularity
Normal Mild to diffuse
mesangial
proliferation, 4/
22 glomeruli
had cellular
crescents
Normal
cellularity and
uniformly thin
capillary loops
None
Treatment P None None P PE/P/Aza PE/P/C PE/P
Prognosis No hemoptysis,
renal function
and urinalysis
remained
normal
No hemoptysis,
no red cells and
a trace of
protein in
urinalysis, with
normal renal
function
No hemoptysis,
renal function
and urinalysis
remained
normal
No hemoptysis,
renal function
and urinalysis
remained
normal
Trace protein
and 0–2 red
cells/HPF in
urinalysis and
normal renal
function
Chest X-ray was
normal,
urinalysis and
renal function
remained
normal
No hemoptysis
and normal
renal function
Follow-up 2 years 5 years 4 years 2 years 2 years 8 years 2 months
A, Azathioprine; C, cyclophosphamide; F, female; GCW, glomerular capillary wall; GBM, glomerular basement membrane; HPF, high power field; IF, immunofluorescence; LM,
light microscopy; M, male; N, no; P, prednisone; PE, plasma exchange; Upr, urine protein.
Data complied from published case reports
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High affinity of the antibodies is another factor that
could contribute to the fulminant nature and treatment
resistance of anti-GBM disease.24 The functional affinity of
this patient’s antibodies was detected by antigen-inhibition
ELISA as described previously.25,26 The functional affinity
constant (aK) was measured as the reciprocal value of molar
concentration of a(IV)NC1 needed for 50% inhibition of
the binding capacity of the antibodies.27 The aK in this case
was 4.0 106 M1, much lower than that of patients with
classic anti-GBM disease (aK 3.26 108 M1).18 Our previous
study has indicated that the functional affinity of anti-GBM
antibody is closely associated with the percentage of
glomerular crescent formation in patients with anti-GBM
disease.26 Therefore, the low affinity of anti-GBM antibodies
of this patient could be another explanation for the less severe
involvement of the kidney.
Other investigators have suggested the possibility that the
presence of antibodies to epitopes other than a3(IV)NC1,
that is, a1(IV)NC1 and a4(IV)NC1 found in a minority
of cases (15%), might lead to differing presentations of
anti-GBM disease.19,28 It does not seem to be of relevance to
the case presented here, as antibodies in this patient reacted
to a3(IV)NC1, exclusively.
The recent detection of natural autoantibodies against
GBM in normal human serum has attracted more attention
to this subset of patients with anti-GBM disease and normal
renal function. Comparing the characteristics of anti-GBM
antibodies in this case with those in healthy persons and in
patients with anti-GBM disease (Table 3),18 we observed that
antibodies in this patient appeared to be more like those
in healthy persons. The long-term follow-up of patients
similar to the case reported herein revealed a good prognosis
for renal function even without treatment. This observation
taken together with the differences in the pattern of anti-
bodies between these patients and those with classic anti-
GBM disease tends to not support the suggestion that these
patients might represent an earlier stage of classic anti-GBM
disease. We speculate that this group of patients may be a
unique subtype of anti-GBM disease. The elucidation of
humoral and cellular immunity in these patients could be
of vital importance in investigations of the pathogenesis of
anti-GBM disease.
The treatment and prognosis of anti-GBM disease with
normal renal function
Individuals with anti-GBM disease and renal impairment or
pulmonary hemorrhage are generally treated with plasma-
pheresis and immunosuppression to preserve any residual
renal function and to control bleeding; following a course of
treatment, antibodies disappear and rarely recur. Patients with
anti-GBM disease and normal renal function have a good
prognosis when treated aggressively; indeed, treatment is
indicated when there is hemoptysis5,7 or when renal histology
is changed.11 Although the use of less aggressive strategies
or supportive treatment has only occasionally been associated
with spontaneous recovery and persistently normal renal
function,5,10 this approach is not recommended.
Conclusion
Anti-GBM disease with normal renal function is not rare.
The key point for diagnosis lies on the physicians to consider
Table 2 | A summary of the clinical features, treatment, and
prognosis of patients with anti-GBM disease and normal
renal function4–12
No. N % (N=13)
Male/female 10:3
Median age, years 22 (18–79)
Exposure to gasoline fumes 4 30.8
Smoke 6 46.2
Macroscopic hematuria 3 23.1
Microhematuria 7 53.8
Proteinuria 10 76.9
BP4140/90 mm Hg 0 0
Hemoptysis 8 61.5
Malaise, fever, LOW 4 30.8
Hbo90 g/l 7 53.8
Chest radiograph abnormality 8 61.5
Circulating anti-GBM antibodies 6 50.0 (N=12)
Renal biopsy
Linear IgG deposition along GCW in IF 13 100
Normal 3 25.0 (N=12)
Proliferation in mesangium 9 75.0 (N=12)
Crescentso50% 2 16.7 (N=12)
Crescents450% 0 0
Treatment
PE 5 38.5
P 10 76.9
C or A 6 46.2
No treatment 3 23.1
Prognosis
Hematuria 4 30.8
Proteinuria 7 53.8
Scrm/Ccrk 0 0
Follow-up, median months 48 (2–96)
A, Azathioprine; BP, blood pressure; C, cyclophosphamide; Ccr, creatinine clearance;
GCW, glomerular capillary wall; GBM, glomerular basement membrane; Hb, hemo-
globin; IF, immunofluorescence; LOW, loss of weight; P, prednisone; PE, plasma
exchange; Scr, serum creatinine.
Table 3 | The difference between natural and disease-
associated anti-GBM antibodies18
Natural
anti-GBM
antibodies
Antibodies in
the current
case
Disease-
associated anti-
GBM antibodies
Percentage
of IgG
0.5 N 1
Titer 1:60 1:400 1:1000
IgG subclasses IgG2 and IgG4 IgG4 Mainly IgG1
and IgG4
AK 9.09 107 M1 4.0 106 M1 3.26 108 M1
GBM, glomerular basement membrane; N, not known.
aK, affinity constant of anti-GBM antibodies, measured as the reciprocal value of
molar concentration of a(IV)NC1 needed for 50% inhibition of the binding capacity
of the antibodies.
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this disease when the patients present with lung hemorrhage
or moderate to severe anemia, and when the urinalysis
revealed minimal abnormalities or even no abnormalities.
Under the aggressive treatment, a good prognosis of
maintaining normal renal function can be expected, in spite
of mild proteinuria or hematuria may leave in some patients.
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